DNA Studio 4 Vault builds on the leading bioprinting software and transforms cumbersome processes riddled with administrative paperwork into the digital era. Providing users with confidence and trust in their documentation, enabling a faster translation from the research lab to the clinic.

A significant challenge in translational research is ensuring the proper scaling of pre-clinical work to a clinical setting. This process comes with significant regulatory requirements that require a high degree of discipline and traceability in terms of processes. One key requirement in this process is the development of trustworthy digital records that provide clear details on actions and activities that have taken place within a process.

With DNA Studio 4 Vault, CELLINK launches a software that builds on its industry leading software platform DNA Studio 4 but provides users with critical features required to support researchers looking to maintain compliance and take their research to a clinical stage. Through features like user authentication, authorization, and validation, DNA Studio 4 Vault addresses some of the necessary critical elements needed to maintain compliance with regulatory requirements.

The launch of this software ushers in a new era of biofabrication. This era has a keen focus on taking research advancements from the last decade and enabling them to become viable clinical solutions. CELLINK is a proud solution provider that is dedicated to growing alongside our customers’ research. We remain committed to supporting our partners on their translational journey by taking their research from the benchtop to the clinic. DNA Studio 4 Vault is the first CELLINK product designed to support this next era of biofabrication.

Read more on DNA Studio 4 Vault’s product page.

For further information, please contact:

Avijit Minocha, Head of Marketing, CELLINK
Email: [email protected]

About CELLINK

CELLINK is creating the future of health as part of BICO, the world’s leading bioconvergence company. When CELLINK released the first universal bioink in 2016, it democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 700 publications and are trusted by more than 1,000 academic, pharmaceutical and industrial labs. At the forefront of the bioprinting industry, CELLINK aims to alleviate organ donor shortage with biofabricated transplantable organs and remains committed to reducing our dependence on animal testing and increasing efficiencies in drug development with more physiologically relevant bioprinted organ models. Visit cellink.com to learn more. BICO is listed on the Nasdaq Stockholm Main Market under BICO.